Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
Sofia, Bulgaria, September 24, 2020 - According to art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, Sopharma AD (3JR: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that on September 23, 2020 the Company sold 5 000 own shares representing 0.0037% of the share capital of the Company, at a total value of BGN 15 700 on the Bulgarian Stock Exchange, the average price per share was 3.1400 BGN.
The total number of treasury shares after this transaction is 8 960 467, representing 6.647% of the share capital of the Company.
Sofia, Bulgaria, September 23, 2020 - According to art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, Sopharma AD (3JR: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that on September 21, 2020 the Company sold 9 000 own shares representing 0.0067% of the share capital of the Company, at a total value of BGN 28 260 on the Bulgarian Stock Exchange, the average price per share was 3.1400 BGN.
The total number of treasury shares after this transaction is 8 965 467, representing 6.651% of the share capital of the Company.